Among its molecular subtypes, triple-negative breast cancer (TNBC), defined by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), exhibits pronounced heterogeneity and aggressive clinical behavior. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.